Last reviewed · How we verify
NCT07301996: Mobile PRO
Randomized Phase II Study to Evaluate Efficacy of Web-based Patient-reported Outcome (PRO) Application in Solid Cancer Patients
NA trial testing Mobile PRO in Solid Cancer in 166 participants. Completed in 21 July 2021.
21 July 2021
Quick facts
| Lead sponsor | Asan Medical Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 166 |
| Start date | 4 February 2021 |
| Primary completion | 21 July 2021 |
| Estimated completion | 21 July 2021 |
| Sites | 1 location across South Korea |
Drugs / interventions tested
- Mobile PRO
- usual care
Conditions studied
- Solid Cancer — all drugs for Solid Cancer →
Sponsor
Asan Medical Center
Who can join
19 and older, any sex, with Solid Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-center, open-label, Phase 2 study to evaluate the feasibility of a mobile PRO and its efficacy in reducing unplanned healthcare utilization (unplanned outpatient visits, emergency department visits, and hospitalizations).
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07301996
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Solid Cancer
Currently open trials in the same condition.
- NCT07242417 — TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07281326 — A Study of AK138D1 in Advanced Malignant Tumors · Phase 1 · recruiting
- NCT06797037 — Proof of Concept to Assess the Feasibility of a Decentralised Pathway Coordinated by the Advanced Practice Nurse for Pat · NA · recruiting
- NCT06771622 — Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · active not recruiting
- NCT06730386 — A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors · Phase 1 · recruiting
Other Asan Medical Center trials
Trials by the same sponsor.
- NCT07530393 — Blood Viscosity and Outcomes After Elective Craniotomy · not yet recruiting
- NCT07010497 — A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Be · Phase 2 · recruiting
- NCT07382505 — Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cerv · not yet recruiting
- NCT07489092 — Feasibility of a Digital Rehabilitation Platform in Patients After ICU Discharge · NA · recruiting
- NCT07431762 — Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprpsthetic Hear · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07301996 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Asan Medical Center
- Last refreshed: 24 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07301996.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing